drugset / Trial / NCT00481676
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study evaluated the safety and efficacy of omalizumab in adult patients with moderate to severe chronic urticaria who exhibit IgE against thyroperoxidase.
Timeline
- Start
- 2007-05
- Primary completion
- 2009-04
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omalizumab | Monoclonal antibody | 75 mg | Subcutaneous |
| Subject | Omalizumab | Monoclonal antibody | 375 mg | Subcutaneous |
| Comparator | Clemastine | Small molecule | — | — |
| Background | Loratadine | Small molecule | — | — |